Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Discontinuation From Treatment	STARTED	Placebo	1,867
Discontinuation From Treatment	STARTED	10 mg Empagliflozin	1,863
Discontinuation From Treatment	Treated	Placebo	1,863
Discontinuation From Treatment	Treated	10 mg Empagliflozin	1,863
Discontinuation From Treatment	COMPLETED	Placebo	1,352
Discontinuation From Treatment	COMPLETED	10 mg Empagliflozin	1,381
Discontinuation From Treatment	NOT COMPLETED	Placebo	515
Discontinuation From Treatment	NOT COMPLETED	10 mg Empagliflozin	482
Discontinuation From Trial	STARTED	Placebo	1,867
Discontinuation From Trial	STARTED	10 mg Empagliflozin	1,863
Discontinuation From Trial	Treated	Placebo	1,863
Discontinuation From Trial	Treated	10 mg Empagliflozin	1,863
Discontinuation From Trial	COMPLETED	Placebo	1,847
Discontinuation From Trial	COMPLETED	10 mg Empagliflozin	1,841
Discontinuation From Trial	NOT COMPLETED	Placebo	20
Discontinuation From Trial	NOT COMPLETED	10 mg Empagliflozin	22

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03057977/flow